Waters Stock Price, News & Analysis

Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute XR Mass Spectrometer, its most advanced benchtop tandem quadrupole system. The new device delivers up to 6x increase in performance robustness compared to the Xevo TQ Absolute, while offering superior sensitivity for pharmaceutical quantitation and PFAS detection. Key features include 50% reduced power and nitrogen gas consumption, 50% less heat production, and 50% smaller bench space footprint compared to competitors. The system incorporates the innovative StepWave XR Ion Guide technology, designed to minimize downtime while maintaining high sensitivity for complex samples. The product has demonstrated impressive performance at Synexa Life Sciences, handling over 20,000 continuous injections of human plasma samples with enhanced reproducibility and accuracy.

Waters Corporation (NYSE:WAT) has launched BioResolve Protein A Affinity Columns with MaxPeak Premier Technology, marking their first entry into affinity chromatography columns. The innovative product delivers up to 7x improvement in sensitivity compared to market leaders, featuring novel non-porous 3.5 μm particles. Key benefits include: enabling measurements up to 2 days earlier for antibody titers, providing 2x more attribute information with simplified workflows, and allowing accurate quantitation at lower concentrations with less sample. The columns, available in 2.1 x 20 mm and 3.9 x 5 mm formats, can be coupled with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system.

Waters Corporation (NYSE:WAT) has acquired Halo Labs, a company specializing in imaging technologies for particle analysis in therapeutic products. The acquisition brings Halo's Aura™ platform, which offers full spectrum particle analysis capabilities complementary to Waters' existing Wyatt Technology™ Portfolio.

The Aura platform's key advantage lies in its ability to detect translucent process impurities in CAR T-cell therapies that are typically undetectable through standard methods. This technology will be integrated into Waters' large molecule development and QA/QC processes, enhancing their analytical capabilities for biopharmaceutical applications.

The acquisition is expected to have a negligible impact on Waters' income statement over the next 12 months.

Waters Corporation (NYSE:WAT) announced that CEO Udit Batra will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th, 2025, at 8:45AM Eastern Time. The event will be webcast live on Waters' Investor Relations website, with a replay available for 90 days.

Waters Corporation is a global leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences. With over 65 years of experience and 7,600+ employees across 100+ countries, the company collaborates with customers in laboratories, manufacturing sites, and hospitals to advance scientific innovation.

Waters Corporation (NYSE:WAT) has integrated Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments from its Wyatt Technology Portfolio with Empower Software. This integration enables biologics data acquisition and quality control analysis, providing significant benefits: • Reduces software validation time by up to 6 months • Cuts analysis time for biotherapeutic peptides and proteins by 20% • Enhances quality control through absolute molecular weight measurements The integration includes DAWN, miniDAWN, and OptiLab Detectors and will be available in July 2025. Empower Software, used in over 80% of novel drug submissions to regulators, now offers improved efficiency and GMP readiness while reducing end-user training requirements in compliant settings.

Waters Corporation reported strong Q1 2025 financial results with sales of $662 million, up 4% as reported and 7% in constant currency. The company saw impressive instrument growth of 11% in constant currency, driven by pharmaceutical and industrial markets. GAAP EPS reached $2.03, while non-GAAP EPS was $2.25, showing 2% growth despite forex headwinds. Given the strong performance, Waters raised its full-year 2025 guidance, projecting constant currency sales growth of 5-7% and non-GAAP EPS of $12.75-$13.05. For Q2 2025, the company expects constant currency sales growth of 5-7% and non-GAAP EPS between $2.88-$2.98.

Waters (NYSE:WAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. The presentation will be accessible through a live webcast on the company's Investor Relations website, with replay availability until June 3rd, 2025.

Waters is a global leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences. The company employs 7,600 people across 100+ countries, working with customers in laboratories, manufacturing sites, and hospitals to advance scientific benefits.

Waters (NYSE:WAT) has expanded its Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, enhancing capabilities for biopharmaceutical development and Quality Control laboratories. The system delivers significant improvements including:

• Up to 80x boost in sensitivity with MaxPeak™ Premier columns
• Over 3x improvement in day-to-day reproducibility
• Reduction in carryover by up to two orders of magnitude
• 40% reduction in common user errors

The platform is designed to simplify laboratory workflows and reduce out-of-specification results. All configurations are controlled by Waters Empower™ Chromatography Data System and support LIMS connectivity. The system has earned ACT Ecolabels from My Green Lab for sustainable manufacturing practices.

Waters (NYSE: WAT) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. CEO Udit Batra Ph.D. will engage in a fireside chat on Tuesday, March 11th, 2025 at 10:00AM Eastern Time.

The event will be accessible through a live webcast on Waters' Investor Relations website, with replay available for 90 days. Waters , with a 65-year legacy, operates globally as a leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences.

• Global presence in over 100 countries
• 7,600 employees worldwide
• Focus on medicine efficacy, food safety, water purity, and product quality
• Collaborates with laboratories, manufacturing sites, and hospitals